If a researcher introduces a novel compound that completely inhibits phospholipase A2 (PLA2) activity in macrophages stimulated with lipopolysaccharide (LPS), which consequence follows regarding the inflammatory response?

💡 Explanation

Inhibiting PLA2 prevents the release of arachidonic acid, the precursor to prostaglandins, because PLA2 catalyzes its release from membrane phospholipids. Therefore, prostaglandin synthesis decreases, attenuating inflammation, rather than increasing leukotriene production or thromboxane synthesis, which depend on different pathways.

• Which adaptation occurs when bone growth obstructs ossicles-oval window interface?
• Why does an ACL tear, disrupting knee joint biomechanics, often result in osteoarthritis years later?
• If a patient with hypertension is prescribed a drug that inhibits the action of aldosterone in the kidneys, which consequence follows?
• A patient with a deiodinase enzyme defect has high T4 levels, yet exhibits hypothyroid symptoms. Why does this condition cause a seemingly paradoxical presentation?
• Why does blood pO₂ often remain normal during moderate anemia, despite reduced hemoglobin?
• Why does septic shock, initiated by a localized bacterial infection, sometimes trigger multi-organ failure distantly, despite antibiotic treatment eliminating the original infection source?